On January 3, 2024 Pacylex Pharmaceuticals, a clinical-stage oncology innovator, reported that it is closing out a pivotal year with a string of accomplishments that validate its first-in-class oral cancer therapy, zelenirstat (Press release, Pacylex Pharmaceuticals, JAN 3, 2024, View Source [SID1234645055]). This momentum positions Pacylex perfectly for a Series B funding round or strategic partnership to fuel the next stage of its exciting journey.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Zelenirstat shines in Phase 1, exceeding expectations:
No Dose Limiting Toxicities (DLTs) up to the target drug exposure. In an all-comer Phase 1 study in refractory/relapsed lymphoma and solid tumor patients, there were no zelenirstat DLTs at doses ranging from 20 mg – to 210 mg.
Evidence of Efficacy. Even in heavily pre-treated patients with resistant cancers like ovarian, colorectal, bile duct, lung, and appendiceal, zelenirstat at the highest dose significantly improved both progression-free and overall survival.
Clinical Advancements. Phase 2a is underway in B-cell NHL (non-Hodgkin lymphoma) at the 210 mg dose. Similar studies are planned for solid tumors and acute myeloid leukemia, further amplifying the potential of zelenirstat across multiple cancer indications.
Beyond Phase 1: Additional achievements solidify zelenirstat’s potential:
Orphan Drug and Fast Track designations for AML. Regulatory recognition validates zelenirstat’s promise in this challenging cancer.
Potent Radiosensitization in Brain Cancer. zelenirstat outperformed standard-of-care treatments in preclinical models, opening doors for combination therapies.
Capital Efficiency and De-risking: Pacylex has progressed to Phase 2 on less than $20 million, demonstrating an ability to deliver results with lean operations.
Investing in the future of cancer treatment:
With zelenirstat demonstrating safety and efficacy in patients who have failed all available therapeutic options, Pacylex presents a compelling investment opportunity. We offer:
A first-in-class therapy with ibrutinib-like potential: zelenirstat targets a novel pathway, potentially surpassing existing treatments in efficacy and tolerability.
Multiple expansion avenues: Solid tumors, AML, and autoimmune disorders represent future growth opportunities.
Experienced and dedicated team: Our team of scientific and commercial leaders possesses a proven track record of success.
Join us in shaping the future of cancer care:
Pacylex is actively seeking Series B funding and strategic partnerships to fuel the next chapter of zelenirstat’s development. We invite investors to connect with us at Biotech Showcase during JPM Week to learn more about this groundbreaking therapy and participate in a truly disruptive force in the oncology landscape.
Meet us through the BIO Partnering. View Source
Meet us through the BTS Partnering. https://informaconnect.com/biotech-showcase/partnering/
Schedule a casual coffee or reception meeting! [email protected]